Veradermics, Incorporated
$73.97
▲
9.2%
2026-04-21 08:02:00
www.veradermics.com
NYQ: MANE
Explore Veradermics, Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.85 B
Current Price
$73.97
52W High / Low
$80.9 / $32
Stock P/E
—
Book Value
$-131.48
Dividend Yield
—
ROCE
-49.88%
ROE
-72.06%
Face Value
—
EPS
$-2.37
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
0
Current Ratio
16.66
Quick Ratio
16.66
Forward P/E
-20.84
Price / Sales
—
Enterprise Value
$2.69 B
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$78.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 2. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 3. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 4. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
| 5. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 6. | Tvardi Therapeutics, Inc. | $3.22 | — | $30.72 M | — | -127.18% | -2.38% | $43.65 / $2.75 | $2.23 |
| 7. | Rani Therapeutics Holdings, Inc. | $0.97 | — | $118.3 M | — | -83.37% | -1.82% | $3.87 / $0.39 | $0.34 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q4 2024 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -22.75 M | -5.58 M |
| Net Profit | -21.85 M | -5.66 M |
| EPS in Rs | -0.59 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -71.56 M | -26.38 M | -17.32 M |
| Net Profit | -70 M | -26.49 M | -16.49 M |
| EPS in Rs | -1.87 | -0.71 | -0.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 152.62 M | 55.53 M | 17.56 M |
| Total Liabilities | 273.63 M | 104.02 M | 39.8 M |
| Equity | -121.01 M | -48.48 M | -22.24 M |
| Current Assets | 152.49 M | 55.53 M | 17.56 M |
| Current Liabilities | 9.15 M | 4.72 M | 3.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -71.6 M | -23.69 M | -13.51 M |
| Investing CF | -118.86 M | 0 M | — |
| Financing CF | 159.14 M | 60.48 M | 13.89 M |
| Free CF | -71.63 M | -23.69 M | -13.51 M |
| Capex | -0.02 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -164.25% | -60.63% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.